Jbf Capital, Inc. Blueprint Medicines Corp Transaction History

Jbf Capital, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$45.57 - $74.26 $1.02 Million - $1.66 Million	-22,322 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$60.96 - $101.18 $701,040 - $1.16 Million	11,500 Added 106.27%	22,322 $1.42 Million
Q1 2018 May 11, 2018	BUY	$73.28 - $102.95 $793,036 - $1.11 Million	10,822 New	10,822 $992,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.